Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | HBB | P68871 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.49 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13019177 | 1.00 | LMNA (0.61) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL19059876 | 1.00 | LMNA (0.61) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL21835519 | 1.00 | LMNA (0.61) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL1847443 | 1.00 | LMNA (0.61) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL15689845 | 1.00 | LMNA (0.61) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL13243124 | 1.00 | LMNA (0.61) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL1847445 | 1.00 | LMNA (0.61) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL14146164 | 0.91 | ALDH1A1 (0.52) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL11794055 | 0.91 | LMNA (0.58) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL15702571 | 0.91 | ALDH1A1 (0.63) | LMNAALDH1A1TP53MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114152-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | Nevada Cancer Institute (US) | 2009-11-11 | — | — | EP | claimed |
| US-20080182806-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | NEVADA CANCER INSTITUTE (US) | 2008-07-31 | — | — | US | claimed |
| WO-2008092127-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | NEVADA CANCER INSTITUTE (US) | 2008-07-31 | — | — | WO | claimed |
| US-20250082661-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2025-03-13 | — | — | US | disclosed |
| US-20250011881-A1 | MYC-HSF1 DUAL AMPLIFICATION AS A BIOMARKER FOR CANCER TREATMENT | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-01-09 | — | — | US | disclosed |
| US-20240309458-A1 | MYC-HSF1 DUAL AMPLIFICATION AS A BIOMARKER FOR CANCER TREATMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-19 | — | — | US | disclosed |
| US-12053482-B2 | Oral formulations of cytidine analogs and methods of use thereof | CELGENE CORPORATION (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4327888-A2 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | Celgene Corporation (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3782612-B1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230255996-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2023-08-03 | — | — | US | disclosed |
| WO-2009139888-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009139888-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2009-11-19 | — | — | WO | disclosed |
| EP-2114152-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | Nevada Cancer Institute (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114152-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | Nevada Cancer Institute (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20090005551-A1 | SYNTHESIS OF 5-AZACYTIDINE | CELGENE INTERNATIONAL SARL (CH) | 2009-01-01 | — | — | US | disclosed |
| WO-2008092127-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | NEVADA CANCER INSTITUTE (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20080182806-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | NEVADA CANCER INSTITUTE (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182806-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | NEVADA CANCER INSTITUTE (US) | 2008-07-31 | — | — | US | disclosed |
| WO-2008092127-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | NEVADA CANCER INSTITUTE (US) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12053482-B2 | Oral formulations of cytidine analogs and methods of use thereof | DCTD, CDA, NT5C2 | LMNA 1285/4885ALDH1A1 2362/4885TP53 241/4885 |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | LMNA 1285/4885ALDH1A1 2362/4885TP53 241/4885 |
| US-20250082661-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | LMNA 1285/4885ALDH1A1 2362/4885TP53 241/4885 |
| US-20230255996-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | LMNA 1285/4885ALDH1A1 2362/4885TP53 241/4885 |
| US-20090005551-A1 | SYNTHESIS OF 5-AZACYTIDINE | TYMS, DNMT1, TET1 | LMNA 2370/4885ALDH1A1 2154/4885TP53 2966/4885 |
| US-20080182806-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | DCTD, DNMT3A, HDAC5 | LMNA 939/4885ALDH1A1 1629/4885TP53 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.